Page 560 - Cardiac Nursing

g
g
Pa
g
ara
ara
36.
51
51
p
009
1:0
1
1
ara
3
3
0/0
3
1 A
1 A
1:0
xd
xd
M
q
0/0
q
q
p
36.
e 5
M
1-5
6/2
e 5
1-5
K34
K34
LWBK340-c22_ pp511-536.qxd 30/06/2009 11:01 AM Page 536 Aptara
0-c
22_
22_
0-c
36
36
009
t
t
Pa
A
p
M
6/2
p
A
p
536 PA R T I V / Pathophysiology and Management of Heart Disease
58. Eisenberg, M. J., & Jamal, S. (2003). Glycoprotein IIb/IIIa inhibition in vascular disease: A statement from the Council on Clinical Cardiology
the setting of acute ST-segment elevation myocardial infarction. Journal of (Subcommittee on Exercise, Rehabilitation, and Prevention) and the
American College of Cardiology, 42(1), 1–6. Council on Nutrition, Physical Activity, and Metabolism (Subcommittee
7
7
59. Topol, E. J. (2001). Reperfusion therapy for acute myocardial infarction on Physical Activity). Circulation, 107(24), 3109–3116.
with fibrinolytic therapy or combination reduced fibrinolytic therapy and 79. Balady, G. J., Ades, P. A., Comoss, P., et al. (2000). Core components of
platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. cardiac rehabilitation/secondary prevention programs: A statement for
Lancet, 357(9272), 1905–1914. healthcare professionals from the American Heart Association and the
7
7
60. ASSENT-3 Investigators. (2001). Efficacy and safety of tenecteplase in American Association of Cardiovascular and Pulmonary Rehabilitation
combination with enoxaparin, abciximab, or unfractionated heparin: The Writing Group. Circulation, 102(9), 1069–1073.
ASSENT-3 randomised trial in acute myocardial infarction. Lancet, 80. Smith, S. C., Jr., Allen, J., Blair, S. N., et al. (2006). AHA/ACC guidelines
358(9282), 605–613. for secondary prevention for patients with coronary and other atheroscle-
61. Aversano, T., Aversano, L. T., Passamani, E., et al. (2002). Thrombolytic rotic vascular disease: 2006 update endorsed by the National Heart, Lung,
7
7
therapy vs primary percutaneous coronary intervention for myocardial in- and Blood Institute. Journal of American College of Cardiology, 47(10),
farction in patients presenting to hospitals without on-site cardiac surgery: 2130–2139.
A randomized controlled trial. JAMA, 287(15), 1943–1951. 81. Cullen, B. (2007). Physicians’ desk reference (Vol. 61). New York: Thomp-
7
7
62. Garcia, E., Elizaga, J., Perez-Castellano, N., et al. (1999). Primary angio- son PDR, Simon & Schuster.
plasty versus systemic thrombolysis in anterior myocardial infarction. 82. Chen, Z. M., Pan, H. C., Chen, Y. P., et al. (2005). Early intravenous then
Journal of American College of Cardiology, 33(3), 605–611. oral metoprolol in 45,852 patients with acute myocardial infarction: Ran-
63. Grines, C. L., Browne, K. F., Marco, J., et al. (1993). A comparison of im- domised placebo-controlled trial. Lancet, 366(9497), 1622–1632.
6
6
mediate angioplasty with thrombolytic therapy for acute myocardial in- 83. CAPRIE Steering Committee. (1996). A randomised, blinded, trial of
farction. The Primary Angioplasty in Myocardial Infarction Study Group. clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
New England Journal of Medicine, 328(10), 673–679. Lancet, 348(9038), 1329–1339.
64. Ribichini, F., Steffenino, G., Dellavalle, A., et al. (1998). Comparison of 84. Kulkarni, R. A. (2000). Clopidogrel in cardiovascular disorders. Journal of
6
thrombolytic therapy and primary coronary angioplasty with liberal stent- Postgraduate Medicine, 46(4), 312–313.
6
ing for inferior myocardial infarction with precordial ST-segment depres- 85. Hofmann, L. V., Razavi, M., Arepally, A., et al. (2001). GPIIb-IIIa recep-
sion: Immediate and long-term results of a randomized study. Journal of tor inhibitors: What the interventional radiologist needs to know. Cardio-
American College of Cardiology, 32(6), 1687–1694. vascular and Interventional Radiology, 24(6), 361–367.
65. The Global Use of Strategies to Open Occluded Coronary Arteries in 86. Berkowitz, S. D., Sane, D. C., Sigmon, K. N., et al. (1998). Occurrence
Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investi- and clinical significance of thrombocytopenia in a population undergoing
gators. (1997). A clinical trial comparing primary coronary angioplasty high-risk percutaneous coronary revascularization. Evaluation of c7E3 for
with tissue plasminogen activator for acute myocardial infarction. New the Prevention of Ischemic Complications (EPIC) Study Group. Journal
6
6
England Journal of Medicine, 336(23), 1621–1628. of American College of Cardiology, 32(2), 311–319.
66. Zijlstra, F., de Boer, M. J., Hoorntje, J. C., et al. (1993). A comparison of 87. McClure, M. W., Berkowitz, S. D., Sparapani, R., et al. (1999). Clinical
immediate coronary angioplasty with intravenous streptokinase in acute my- significance of thrombocytopenia during a non-ST-elevation acute coro-
ocardial infarction. New England Journal of Medicine, 328(10), 680–684. nary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Re-
67. Antman, E. M., Cohen, M., Bernink, P. J., et al. (2000). The TIMI risk ceptor suppression using integrilin therapy (PURSUIT) trial experience.
score for unstable angina/non-ST elevation MI: A method for prognosti- Circulation, 99(22), 2892–2900.
cation and therapeutic decision making. JAMA, 284(7), 835–842. 88. Antman, E. M., McCabe, C. H., Gurfinkel, E. P., et al. (1999). Enoxa-
68. Boersma, E., Pieper, K. S., Steyerberg, E. W., et al. (2000). Predictors of parin prevents death and cardiac ischemic events in unstable angina/non-
outcome in patients with acute coronary syndromes without persistent ST- Q-wave myocardial infarction. Results of the thrombolysis in myocardial
segment elevation. Results from an international trial of 9461 patients. infarction (TIMI) 11B trial. Circulation, 100(15), 1593–1601.
The PURSUIT Investigators. Circulation, 101(22), 2557–2567. 89. Cohen, M., Demers, C., Gurfinkel, E. P., et al. (1997). A comparison of
69. Eagle, K. A., Lim, M. J., Dabbous, O. H., et al. (2004). A validated pre- low-molecular-weight heparin with unfractionated heparin for unstable
diction model for all forms of acute coronary syndrome: Estimating the coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin
risk of 6-month postdischarge death in an international registry. JAMA, in Non-Q-Wave Coronary Events Study Group. New England Journal of
291(22), 2727–2733. Medicine, 337(7), 447–452.
7
7
70. Granger, C. B., Goldberg, R. J., Dabbous, O., et al. (2003). Predictors of 90. Ferguson, J. J., Califf, R. M., Antman, E. M., et al. (2004). Enoxaparin vs
hospital mortality in the global registry of acute coronary events. Achieves unfractionated heparin in high-risk patients with non-ST-segment elevation
of Internal Medicine, 163(19), 2345–2353. acute coronary syndromes managed with an intended early invasive strategy:
71. Pollack, C. V., Jr., Sites, F. D., Shofer, F. S., et al. (2006). Application of Primary results of the SYNERGY randomized trial. JAMA, 292(1), 45–54.
the TIMI risk score for unstable angina and non-ST elevation acute coro- 91. Simons, M. (2008). Direct thrombin inhibitors. Anticoagulant therapy in
nary syndrome to an unselected emergency department chest pain popu- unstable angina and acute non-ST elevation myocardial infarction. Up-
lation. Academic Emergency Medicine, 13(1), 13–18. ToDate Online, version 16.3, accessed August, 2008
72. Flaker, G. C., Warnica, J. W., Sacks, F. M., et al. (1999). Pravastatin pre- 92. Kastrati, A., Neumann, F. J., Mehilli, J., et al. (2008). Bivalirudin versus
vents clinical events in revascularized patients with average cholesterol unfractionated heparin during percutaneous coronary intervention. New
concentrations. Cholesterol and Recurrent Events CARE Investigators. England Journal of Medicine, 359(7), 688–696.
Journal of American College of Cardiology, 34(1), 106–112. 93. Aschenbrenner, D. S. (2009). Drugs affecting coagulation. In D. S. As-
73. Chobanian, A. V., Bakris, G. L., Black, H. R., et al. (2003). The Seventh chenbrenner & S. J. Venable (Eds.), Drug therapy in nursing (3rd ed., pp.
Report of the Joint National Committee on Prevention, Detection, Eval- 594–626). Philadelphia: Lippincott Williams & Wilkins.
uation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 94. Simons, M. (2008). Fondaparinux. Anticoagulant therapy in unstable
289(19), 2560–2572. angina and acute non-ST elevation myocardial infarction UpToDate On-
74. Agency for Health Care Policy & Research. (1996). Clinical practice guide- line, version 16.3, retrieved date August, 2008
lines: Number 18: Smoking cessation (AHCPR Publication No. 96-0692). 95. Fondaparinux Drug Information. (2008). UpToDate Online, version
Retrieved from. 16.3, Accessed January 2009.
75. Tonstad, S., Tønnesen, P., Hajek, P., et al. (2006). Effect of maintenance 96. Antman, E. M., & Braunwald, E. (2001). Acute myocardial infarction. In
therapy with varenicline on smoking cessation: A randomized controlled E. Braunwald (Ed.), Heart disease: A textbook of cardiovascular medicine
6
6
trial. JAMA, 296(1), 64–71. (6th ed., Vol. 2, pp. 1114–1231). St. Louis, MO: W.B. Saunders.
76. Ahmed, S., Cannon, C. P., Murphy, S. A., et al. (2006). Acute coronary 97. Dzavik, V., & Hochman, J. S. (2005). Cardiogenic shock and heart fail-
syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the ure complicating acute myocardial infarction. In E. Topol (Ed.), Acute
7
7
PROVE IT-TIMI 22 trial. European Heart Journal, 27(19), 2323–2329. coronary syndromes (3rd ed., pp. 657–687). New York: Marcel Dekker.
77. Thompson, P. D. (2005). Exercise prescription and proscription for pa- 98. Chesebro, J. H., Knatterud, G., Roberts, R., et al. (1987). Thrombolysis
tients with coronary artery disease. Circulation, 112(15), 2354–2363. in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between in-
78. Thompson, P. D., Buchner, D., Pina, I. L., et al. (2003). Exercise and travenous tissue plasminogen activator and intravenous streptokinase.
6
physical activity in the prevention and treatment of atherosclerotic cardio- Clinical findings through hospital discharge. Circulation, 76(1), 142–154.
6